News

Aura Biosciences to Participate in Upcoming Investor Conferences

February 9, 2023 PDF Version BOSTON–(BUSINESS WIRE)–Feb. 9, 2023– Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: Live webcasts of the SVB fireside chat and…

Read more

Aura Biosciences to Participate in Upcoming Investor Conferences

November 8, 2023 BOSTON–(BUSINESS WIRE)–Nov. 8, 2023– Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: The live webcasts of the presentation and fireside chat will…

Read more

Aura Biosciences to Participate in the JMP Securities Life Sciences Conference

May 12, 2023 PDF Version BOSTON–(BUSINESS WIRE)–May 12, 2023– Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023, at 2:00…

Read more

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

October 2, 2023 PDF Version J. Jill Hopkins, M.D., Appointed as Chief Medical Officer and President of Research & Development Mark Plavsic, Ph.D., Appointed as Chief Technology Officer BOSTON–(BUSINESS WIRE)–Oct. 2, 2023– Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced…

Read more

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

November 9, 2023 Received FDA Agreement Under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical Trial Positive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing Phase 2 Clinical Trial with Suprachoroidal Administration Presented at AAO 2023 Preliminary Data from Phase 1 Trial in Bladder Cancer – First Patient Utilizing…

Read more

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

August 9, 2023 PDF Version Strengthened Clinical and Regulatory Leadership Team with Key Appointments Start-up Activities for the Global Phase 3 Trial Ongoing with Release of Drug Product Manufactured with Commercial Process and First Patient Expected to be Dosed in 2H 2023 BOSTON–(BUSINESS WIRE)–Aug. 9, 2023– Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a…

Read more